Xencor (XNCR) stock

Antibody medicines , market cap $2.6B

Antibody medicines

Worth $2.6B

$39.39

+2.07%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Above Average

In its industry

#10of 90

Pharma

Checks firing

8of 14

Trending up

From 52-week high

-1.7%

under its best in a year

Up:Highest Quality Score since Feb 2023. Scores before Sep 10, 2026 were rebuilt.

XNCR's Quality Score was unchanged on Tue, Nov 10, at 14.

Follow XNCR's trial news. Pro members can get an alert when Xencor files news, and see its trials, share raises, and its CEO's filings.

Get an alert when XNCR files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“Enrollment expectations continue to support a XENITH-UC blinded interim analysis around year-end 2026…”Trial data · SEC filing · Nov 4

Cash$378M in cash. One of the last four quarters brought cash in while the others used it.On Sep 30 · the company says “into 2029”

Why is XNCR up?

Up 35% from Oct 29 to Nov 10.

It reported diluted EPS of $0.50 on Nov 4.

Sources: Price history, Nov 10, 2026; SEC filing, Nov 4, 2026

1 more reason, free with an account →2 more reasons why XNCR rose 35% since Oct 29, from its filings, with the other side, how the business stands, the timeline, and its peers, for Pro members.

Key facts on XNCR

Key facts on XNCR
The company	Sales up 34% on the year
Its score	Up:Highest Quality Score since Feb 2023 Scores before Sep 10, 2026 were rebuilt.
Latest filing	8-K, Nov 4 Reported its quarterly results

1 more reason behind XNCR's 14, free with an account →5 more reasons behind XNCR's 14, for Pro members.

XNCR in the news

Mon Nov 9Show Me The Money: Xencor (XNCR) Delivers Triple-Digit Gains, With XENITH-UC Poised For The Next Act RTTNews and 1 more XNCR closed +7.9% that day.

Outlet counts from the GDELT Project.

Cash$378M in cash. One of the last four quarters brought cash in while the others used it.On Sep 30 · the company says “into 2029”

XNCR catalysts

Coming up

After its last 4 reports it closed +1.4% on average, higher 2 of 4 times.

4 more coming up and 14 past catalysts since 2019, with sizes and sources, for Pro members.

What's next for XNCR, and how long its cash lasts

Next step the company has named

End of 2026“Enrollment expectations continue to support a XENITH-UC blinded interim analysis around year-end 2026 and reaching the primary endpoint analysis of the 12-week induction period in the…”Trial data · SEC filing · Nov 4

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: XmAb942 in Healthy Participants and Participants With Ulcerative ColitisPhase 1/2 · Recruiting · 270 people · main data estimated Dec 2027 · NCT06619990

7 more trials, 5 more milestones and 38 filings, for Pro members.

Cash runway Sep 30 balance sheet

$378M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into 2029” (8-K, Nov 4).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Feb 25, 2026)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Ellen Feigal sold 6,843 shares on Jun 18, under a planned sale. 12 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Bassil Dahiyat buys or sells

For Pro members: every trade, and Bassil Dahiyat’s 19 filings and quotes.

Get an alert when XNCR files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why XNCR scores 14

Above Averagefor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. XNCR scores 14 today, against a median of 5 over its last 20 recorded sessions.

+8Chart checks 8 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
News adds

No effect today: Size, Dilution, and Persistence.

What every line is worth, and the reason behind it, on XNCR and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:56 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when XNCR's Quality Score turns up

A free account. No card.

How XNCR ranks in Pharma

XNCR is #10 of 90 by Quality Score.

How XNCR ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	10/14	23
2	LLYEli Lilly	8/14	21
3	PFEPfizer	6/14	17
	VTRSViatris		Open for its score
	WVEWave Life Sciences		Open for its score
	ZTSZoetis		Open for its score
	ZYMEZymeworks		Open for its score
10	XNCRXencor	8/14	14

Share count against a year before: XNCR +2.4%, RCUS +20%, KNSA +4.7%, AUPH +1.2%.

When does XNCR report earnings, and what happens after?

Expected to report Wed Feb 24, after the close (in 106 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What XNCR reported on Nov 4, 2026

The quarter

A profit of $0.50 a share, from a loss of $0.08.

“Revenue earned in the third quarter of 2026 was primarily due to royalty revenue from Alexion and Incyte and milestone revenue from Astellas.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Royaltyup 317%	$87.5M75%	$41.2M80%	$21M100%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 4)

1 more line, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
End of 2026
Cash, cash equivalents and marketable debt securities	$480M to $500Mraised

Figures as filed (SEC filing, Nov 4)

In the company's words

“Decreased other income, net, for the third quarter of 2026, compared to 2025, is primarily due to lower unrealized gains on an equity security.”

From its results filing (SEC filing · Nov 4)

2 more sentences, for Pro members.

The numbers

Market value: $2.6B; today
Sales: $200M; up 33.5% on the year
Free cash flow: -$176M; last 12 months

Sales grew 0.5% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 5.3% a year over 5 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on XNCR: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-5.4%+0.8%-2.8%

May 6Aug 5Nov 4

Reported	When	Gap	Reaction	5 days
Nov 4, 2026After close	After close	+1.5%	-2.8%	not yet
Aug 5, 2026After close	After close	+10.7%	+0.8%	+16.8%
May 6, 2026After close	After close	-2.8%	-5.4%	-4.8%

XNCR closed higher after 2 of its last 4 reports.

All 4 reports, and XNCR's Quality Score going into each

XNCR sales and profit by year

Sales and profit by year

Sales grew in four of the last seven years, to $126M in 2025. It made a profit in two of the eight years.

XNCR has 8 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on XNCR, and all 14 on every stock.Get in free →

XNCR RSI today: 81.6, above its 50-day and 200-day averages

Not scored

RSI 81.6, MACD above signal, above both averages. Not scored.13 readings

The deep dive on XNCR

What it does and how it makes money3 findingsRoyalties made up 64% of its revenue in fiscal 2025 ($80.3M of $126M), against 61% in fiscal 2024; milestone 36%.SEC filing · Feb 25, 2026
Where it stands2 findingsFor Pro members2 findings on where XNCR stands: its cash, debt, and share count, for Pro members
What changed in its filings9 findings"On February 11, 2025, the Company filed for inter partes review of Merus’ U.S. Patent Nos. 9,358,286 and 11,926,859 before the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board seeking a finding that certain claims of those patents are unpatentable." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 4, 2026A new heading in its "Risk Factors" this year: "We may not be able to protect our intellectual property rights throughout the world." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 25, 2026, against the one of Feb 27, 2025
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades XNCR, for Pro members
Against its closest peers4 peersShare count against a year before: XNCR +2.4%, RCUS +20%, KNSA +4.7%, AUPH +1.2%.

14 more findings on XNCR, each with its source, for Pro members.

XNCR share count over time

Shares: 2.4% more than a year ago (to Sep 30).

Shares of XNCR outstanding, as filed
Shares outstanding	As of
75M	Oct 30, 2026
74.4M	Jul 31, 2026
74.1M	May 1, 2026
73.3M	Feb 17, 2026

Offerings, shelves, and splits of XNCR, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Feb 25, 2026
Raised $119.4M in a sale of shares, about 5% of its market value	Sep 12, 2024

XNCR insider trades

XNCR trades by Congress and the executive branch

One trade disclosed in the last six months. The newest:

SellDonald Trump$1K to $15KPresident (R)traded Jul 29, disclosed Sep 22(55 days later)

SellDonald TrumpPresident (R)$1K to $15Ktraded Jul 29, disclosed Sep 22(55 days later)

See what Congress is buying across the market

XNCR's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Bassil I. DahiyatPresident & CEO · 4 trades
Bart Jan CornelissenSr. Vice President & CFO · 2 trades
John R. DesjarlaisSr. Vice President & CSO · 4 trades
Celia EckertSVP, General Counsel · 3 trades
Kevin Charles GormanDirector · 1 trade
Kurt A. GustafsonDirector · 1 trade
Alan Bruce MontgomeryDirector · 1 trade
Ellen FeigalDirector · 1 trade

4 more officers and directors file at XNCR.

See insider trades by person

Which ETFs hold XNCR?

In ETFs: XNCR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Xencor

Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

260 employeesPasadena, CAxencor.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on XNCR and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move XNCR's score: 6 things
5 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 22Donald Trump sold XNCR$1K to $15K, disclosed Sep 22

Alerts are optional.

See XNCR's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: XNCR's Quality Score is 14 (Above Average), #10 of 90 in Pharma.

What does XNCR's Quality Score say?

XNCR scores 14 today, which Breakaway calls Above Average. It is #10 of 90 in Pharma by Quality Score, with 8 of 14 chart checks firing. Up 35% from Oct 29 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is XNCR's Quality Score?

XNCR scores 14 today, which Breakaway calls Above Average (11 to 14). That is #10 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind XNCR's 14.

When does XNCR report earnings?

Expected to report Wed Feb 24, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. XNCR closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.